There was no statistically significant difference in BCSS between patients with ER-negative/PR-positive and ER-negative/PR-positive tumors in the subgroups of male, other race, adjusted AJCC sixth edition stages III and IV, tumor grades III and IV, other histology types, or any ERBB2 status (eTable 2 in the Supplement). The gene discussed is ESR1; the disease is neoplasm.